Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

doi:10.1093/annonc/mdy333

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2018

Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle M A, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel K-O, Thomas R, Zander T, Schultheis A M, Büttner R, Wolf J

Abstract excerpt

Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Adenosquamous

Share to Carcinoma, Non-Small-Cell Lung

Share to Gene Rearrangement

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 30165392
DOI: 10.1093/annonc/mdy333
PMCID: PMC6225899

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.PMID 30165392Read ↗

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysisSemantic proximity Read ↗

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.Semantic proximity Read ↗

TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosisSemantic proximity Read ↗

Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.Semantic proximity Read ↗

TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.Semantic proximity Read ↗

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.